Polypyridyl Ruthenium(II) Complexes with Red-Shifted Absorption: New Promises in Photodynamic Therapy

In the field of cancer photodynamic therapy (PDT) research, development of metal-based PDT drugs that can be used under red light exposure is the "holy grail" to achieve. This highlight highlighted few current literatures on polypyridyl-based Ru(II) complexes with significantly red-shifted absorption to achieve in-vitro and in-vivo PDT effect in 540-600 nm light. The enormous potential of judicial ligand choice and in-silico optimization to achieve the red light, metal-based PDT drugs are discussed.